Klinisk Biokemi i Norden · 2 2013
| 37
grams when preferable; e.g. the protein survey [
2
]
and studies of interferences in common measuring
systems [
3
].
• Prepare a list of Nordic nomenclature for EQA
programs originating from international recom-
mendations.
• Interpret the Helsinki declaration and rules for good
clinical practice regarding the use of patient samples
in EQA programs [
4
].
• Develop common strategies towards authorities
regarding requirements for safety (infectious agents,
dry ice for transport), packaging, mailing of samples
used in EQA programs, and for custom rules.
• Exchange information about available packing mate-
rials and mailing companies.
Current convener, secretariat and representatives
Gunnar Nordin
Equalis
Box 977
SE 751 09 Uppsala, Sweden
E-mail:
Current (2012) representatives: Inger Plum and
Gitte M. Henriksen (DEKS), Harri Laitinen and
Jonna Pelanti (Labquality), Ingunn Þorsteinsdóttir
(KLLÍ), Gunn BB Kristensen (NKK), Sverre Sand-
berg (NOKLUS), Gunnar Nordin and Anna Karlsson
(EQUALIS).
Former conveners
Minna Loikkanen. . . . . . . . . . 2009 – 2011
Pål Rustad. . . . . . . . . . . . . 2006 – 2008
Inger Plum. . . . . . . . . . . . . 2004 – 2005
Gunnar Nordin . . . . . . . . . . 2002 – 2003
Elin Ólafsdóttir . . . . . . . . . . 2000 – 2001
Kristoffer Hellsing. . . . . . . . . 1999
Raimo Tenhunen . . . . . . . . . . 1997 – 1998
Heidi Steensland . . . . . . . . . . 1995 – 1996
Adam Uldall. . . . . . . . . . . . 1993 – 1994
References
1. Pedersen MM, Örnemark U, Rustad P, Steens-
land H, Loikkanen M, Ólafsdóttir E, et al. The
Nordic Trueness Project 2002: use of reference
measurement procedure values in a general
clinical chemistry survey. Scan J Clin Lab Invest
2004;64:309-320.
2. Carlström A, Gävert J, Hellsing K, Milford
Ward A, Ólafsdóttir E, Steensland H, et al.
Improvement of the Quality of Protein Analysis
in Nordic Countries - a Comparative Study.
Klinisk Kemi i Norden 1993;5:6-12.
3. Uldall A, Loikkanen M, Ólafsdóttir E, Örne-
mark U, Nordin, G, Steensland, H. Nordic
interference study, March 2002 - Effects of
haemoglobin and bilirubin on some common
serum analysis, NQLM Report, March 2003.
4. World Medical Association Declaration of Hel-
sinki. Ethical Principles for Medical Research
Involving Human Subjects.
.
net/en/30publications/10policies/b3/17c.pdf
(Accessed Nov 2012)
The following statutes for
EQAnord have been agreed upon:
1. EQAnord consists of one representative from
Iceland and two from each of Denmark, Fin-
land, Norway (one from NKK and one from
NOKLUS) and Sweden. The representatives
are chosen by each member organization.
2. The aim of EQAnord is to provide a forum for
exchange of knowledge about quality related
matters in laboratory medicine – especially to
EQA programs – arising mainly in Nordic and
European countries. It can furthermore initiate
projects in mutually agreed topics of common
interest according to an agreed protocol.
3. EQAnord appoints a convener among its
members for a functioning period of two years.
4. The meeting frequency should be at least
once a year. The participants may be different
from the regular member list as decided by
the convener.
5. The arrangement and costs of the EQAnord
meetings are circulated among the national
EQA organizations. Travel and hotel expenses
are covered by the participant’s national EQA
organization.
These statutes were originally agreed upon in
December 1993 and have thereafter been revie-
wed and updated in March 1998, September
2007 and November 2012.
